HIV-1 capsid mutants inhibit the replication of wild-type virus at both early and late infection phases

FEBS Lett. 1997 Sep 29;415(2):231-4. doi: 10.1016/s0014-5793(97)01132-0.

Abstract

In-frame mutations were introduced into various portions of the human immunodeficiency virus type 1 (HIV-1) gag gene, and potentials of the mutants to suppress the replication of wild-type HIV-1 were monitored. In contrast to results obtained with matrix and nucleocapsid mutants, almost all capsid mutants blocked HIV-1 replication completely in single-round replication assays. A capsid mutant designated C6b was demonstrated to be one of the most efficient inhibitors for HIV-1 reported to date, and to be effective at both early and late viral replication phases. T-cells, which are engineered to express the C6b Gag in response to HIV-1 infection, were perfectly resistant to HIV-1.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Blotting, Western
  • CD4-Positive T-Lymphocytes / virology
  • Capsid / chemistry
  • Capsid / genetics*
  • Capsid / physiology
  • Chloramphenicol O-Acetyltransferase / genetics
  • Chloramphenicol O-Acetyltransferase / metabolism
  • Gene Expression
  • Gene Products, gag / genetics
  • Gene Products, gag / physiology*
  • Genes, gag*
  • Genetic Vectors
  • HIV-1 / genetics*
  • HIV-1 / physiology*
  • Humans
  • Mutagenesis
  • Mutation
  • Transfection
  • Tumor Cells, Cultured
  • Virus Replication*

Substances

  • Gene Products, gag
  • Chloramphenicol O-Acetyltransferase